Faculty: Vladimir Tesar Faculty: Meghan Sise, MD Managing patients with focal segmental glomerulosclerosis, or FSGS, can present certain challenges. FSGS is a serious, progressive condition that has no current FDA-approved treatment and standard of care therapy may not meet treatment goals for many patients. But the current use of patient-reported outcomes (PROs), as well as emerging treatments on the horizon, may prove to be valuable tools in shaping the future of FSGS care.

Faculty: Meghan Sise, MD Managing patients with focal segmental glomerulosclerosis, or FSGS, can present certain challenges. FSGS is a serious, progressive condition that has no current FDA-approved treatment and standard of care therapy may not meet treatment goals for many patients. But the current use of patient-reported outcomes (PROs), as well as emerging treatments on the horizon, may prove to be valuable tools in shaping the future of FSGS care.

Faculty: Vladimir Tesar Faculty: Meghan Sise, MD Managing patients with focal segmental glomerulosclerosis, or FSGS, can present certain challenges. FSGS is a serious, progressive condition that has no current FDA-approved treatment and standard of care therapy may not meet treatment goals for many patients. But the current use of patient-reported outcomes (PROs), as well as emerging treatments on the horizon, may prove to be valuable tools in shaping the future of FSGS care.

Faculty: Meghan Sise, MD Faculty: Vladimir Tesar Managing patients with focal segmental glomerulosclerosis, or FSGS, can present certain challenges. FSGS is a serious, progressive condition that has no current FDA-approved treatment and standard of care therapy may not meet treatment goals for many patients. But the current use of patient-reported outcomes (PROs), as well as emerging treatments on the horizon, may prove to be valuable tools in shaping the future of FSGS care.

Faculty: Vladimir Tesar Faculty: Meghan Sise, MD Managing patients with focal segmental glomerulosclerosis, or FSGS, can present certain challenges. FSGS is a serious, progressive condition that has no current FDA-approved treatment and standard of care therapy may not meet treatment goals for many patients. But the current use of patient-reported outcomes (PROs), as well as emerging treatments on the horizon, may prove to be valuable tools in shaping the future of FSGS care.

Faculty: Kenneth Lieberman, MD Managing patients with focal segmental glomerulosclerosis, or FSGS, can present certain challenges. FSGS is a serious, progressive condition that has no current FDA-approved treatment and standard of care therapy may not meet treatment goals for many patients. But the current use of patient-reported outcomes (PROs), as well as emerging treatments on the horizon, may prove to be valuable tools in shaping the future of FSGS care.

Faculty: Meghan Sise, MD Managing patients with focal segmental glomerulosclerosis, or FSGS, can present certain challenges. FSGS is a serious, progressive condition that has no current FDA-approved treatment and standard of care therapy may not meet treatment goals for many patients. But the current use of patient-reported outcomes (PROs), as well as emerging treatments on the horizon, may prove to be valuable tools in shaping the future of FSGS care.

Faculty: Kenneth Lieberman, MD Faculty: Vladimir Tesar Managing patients with focal segmental glomerulosclerosis, or FSGS, can present certain challenges. FSGS is a serious, progressive condition that has no current FDA-approved treatment and standard of care therapy may not meet treatment goals for many patients. But the current use of patient-reported outcomes (PROs), as well as emerging treatments on the horizon, may prove to be valuable tools in shaping the future of FSGS

Listen to 130 Future Now ShowThis week we havegeopolitical concerns, and criticize legacy media calls for war. We thenexplore theories ofquantum consciousnessand reality splits. We then focus oncelestial eventslike the interstellar comet 3I/ATLAS, along with the threat of asteroids, which leads to a discussion aboutspace exploration and militarization, contrasting NASA’s historical role with the newly formed Space Force. Our conversation also touches on the latest onextraterrestrial lifeon

From carrot flowers to potting soil made of concrete waste – could local, organic and eco-friendly bouquets be the future of floristry? In France, nine out of 10 flowers are imported, but that's starting to change. After decades of being overshadowed by the Netherlands, fierce global competition and strict regulations, the country's flower industry is bouncing back. We met with French florists, farmers and scientists who are behind a blooming revolution to revive "les fleurs françaises".

In this short podcast, recorded on a hot day in mid August, we discuss heat stroke in dogs in hot weather, the link between ear disease and swimming and how to help a dog terrified of going up stairs, a cat that's started howling at night.

Charlie Boocock-Yee, a Masters student in Zoology, studies the ear bones of fossilised fish to find out about their lives.Broadcast on OAR 105.4FM Dunedin www.oar.org.nz

QIAGEN CLC Genomics Workbench allows easy construction and customization of variety of bioinformatic analysis workflows such as DNA-seq, RNA-seq, De Novo Assembly and more. Per feedback received, this session will focus on• A quick and brief introduction to CLC Genomics Workbench• How to construct a workflow• How to add or remove different steps• How to customize different parameters• How to execute the workflow• (Optional) How to install the workflow

Nurturing Creativity Skills: How to Cultivate a Flourishing Mind

Host: Ashley Baker, MSN, PMHNP Guest: Alyssa Schlenz Guest: Shannon Phillps Families of children with sickle cell disease have noted both an abundance of support and significant obstacles when accessing care, ranging from knowledgeable providers and flexible scheduling to transportation concerns and insurance holdups. Joining Ashley Baker to discuss their recent research on these key facilitators and barriers are Drs. Alyssa Schlenz and Shannon Phillips. Dr. Schlenz is an

Matt and Kevin take a humbling look back a classic 1989 immunology paperfrom the lab of David Baltimore (RIP) in which the gene encoding RAG-1, one of two genes that is responsible for the VDJ recombination - a mechanism for the generation of diversity in the adaptive immune system.

For his first interview as CEO of Myriad Genetics, Sam Raha joined us to help kick off Mendelspod’s 15th season. Raha, who took the helm in April after serving as COO and holding senior roles at Illumina and Agilent, leads Myriad at a pivotal moment. While consumer genomics has faltered—23andMe filed for bankruptcy earlier this year—Myriad continues to double down on its clinical strategy with new offerings in oncology, prenatal testing, and mental health.* 0:00 New MRD and HRD testing* 5:30 What

Part 2 of our time in the woods with naturalist Sandy Geffner. This time, Sandy leads Steve and Bill on a “hike”—though with Sandy, the word takes on a different meaning. You might not cover much distance, but you’ll travel miles in understanding: exploring ecology and hearing stories of the forest and the wildlife within it. Enjoy!This episode was recorded on July 21, 2025 at JP Nicely Memorial Park in West Falls, NY.Episode Notes and LinksSandy’s favorite books: A Sand County Almanac by Aldo

Brain Organization 02Music ‘Shotgun Loudmouth’ by Battery Life

Faculty: David Boyer, MD Faculty: Diana V. Do, MD This CME activity focuses on multiwavelength photobiomodulation (PBM), an emerging therapy indicated for the treatment of dry age-related macular degeneration (AMD). Hear from leading researchers and retina specialists about the mechanism of action, how it is administered, its efficacy and safety profile, therapeutic durability, which patients may benefit the most, and how PBM would fit into the AMD treatment paradigm.